With the Federal Reserve considering fewer meetings and less frequent policy guidance, investors are facing a market that may swing more sharply on every new economic data point. That makes it even more important to understand which large cap defensive stocks could hold up better when headlines create noise. This article looks at 3 stocks from a Large Cap Defensive Stocks screener that appear closely linked to this potential shift in Fed communication. You will see how each stock could be positively exposed to this changing backdrop, and where the key risks might sit before you decide whether they deserve a place on your watchlist.

SSE (LSE:SSE)

Overview: SSE is a UK-based energy utility that generates power from renewables and thermal plants, runs high voltage transmission and distribution networks, and supplies electricity to around 4 million homes and businesses. It focuses on owning and operating critical infrastructure that keeps the lights on across large parts of England and Scotland.

Operations: SSE generates most of its revenue from SSE Energy Markets at £7.5b, SSE Thermal at £5.1b and Energy Customer Solutions at £4.9b, with additional contributions from SSE Renewables at £1.6b, SSEN Distribution at £1.2b, SSEN Transmission at £1.2b and corporate activities at £0.5b, primarily across the UK and Ireland.

Market Cap: £28.3b

SSE gives you a mix of regulated networks, a growing renewables portfolio and a cash return profile that many investors look for when the Fed hints at less frequent guidance. Regulated transmission and distribution can offer relatively predictable, inflation-linked returns, while large-scale wind and hydro projects tie the company closely to the UK’s decarbonisation plans. At the same time, a P/E above sector averages, high leverage and dividends that are not well covered by free cash flow mean you are paying up for that stability and growth pipeline. Recent earnings and revenue figures show steady progress. The key question is whether SSE’s balance of income, growth projects and regulatory risk still justifies its premium in a more volatile market for central bank signals.

SSE’s regulated income and renewables pipeline could be masking a bigger story about what you are really paying for. Before you assume the premium P/E is justified, scan the 2 key rewards and 2 important warning signs

ResMed (RMD)

Overview: ResMed is a global healthcare company that makes devices and cloud software to diagnose and treat sleep apnea and other breathing disorders, as well as digital tools that help home care and senior care providers run their operations more efficiently.

Operations: ResMed generates most of its revenue from Sleep and Breathing Health at about US$4.9b, with Residential Care Software contributing around US$671m.

Market Cap: US$30.1b

ResMed can interest investors looking for steadier demand if the Fed follows through on less frequent guidance and market swings pick up. The company sits at the intersection of sleep health, respiratory care and cloud software, with sleep and breathing devices supported by higher margin digital platforms such as AirView and Brightree. Earnings and margins have been improving, and the stock trades on a lower P/E than many US medical equipment peers, which may appeal to investors seeking healthcare exposure without paying a premium. At the same time, pricing pressure, reimbursement changes and rising competition from GLP 1 drugs and rival devices could weigh on its hardware focused model. Understanding how these factors balance out is important before deciding where ResMed fits on a watchlist.

ResMed’s mix of sleep devices and higher margin cloud software could be masking where the real value sits. Scan the analyst forecasts for ResMed before the market fully prices in one crucial twist.

Stryker (SYK)

Overview: Stryker is a global medical technology company that supplies implants for joint replacement and trauma surgeries, surgical equipment, robotics, and stroke and neurovascular products to hospitals and doctors, with a growing focus on digital tools and virtual care platforms.

Market Cap: US$133.4b

Stryker offers investors a large cap healthcare stock with exposure to aging populations, rising procedure volumes and hospital digitization, which can appeal when the Fed considers less frequent guidance and market swings become sharper. Earnings growth has recently outpaced the wider medical equipment sector, margins are moving higher, and recent product launches like the Mako RPS robotic system support its position in orthopaedics. At the same time, high debt, ongoing supply chain and cybersecurity recovery work, regulatory delays and pricing pressure in markets such as China indicate that execution risk is present. The key consideration is whether Stryker’s mix of robotics, digital care and global hospital spend justifies paying a premium for what is viewed by some investors as a quality compounder.

Stryker’s robotics and digital care story is accelerating. Yet many investors still treat it like a plain hospital equipment stock. Read the analysis report for Stryker and see what its premium might really be signalling next

The three stocks covered here are only a starting point, since the full Large-Cap Defensive Stocks screener surfaced 11 more companies with equally compelling stories that could fit your watchlist. To identify the specific catalysts and narratives that matter most to you across this broader group, analyze the Large-Cap Defensive Stocks screener.

Take Control of Your Investment Journey

If SSE or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Stocks

Fresh ideas move first. Screeners help you spot stocks building quiet momentum, staging potential breakouts or dropping into value territory before the crowd catches on, so act now.

• Chase early-stage momentum in smaller companies that still show solid financials by reviewing the curated 48 elite penny stocks with strong financials before they move out of your preferred range.
• Spot quality opportunities that may trade below fair value by scanning a carefully filtered set of 8 high quality undervalued stocks while the relationship between price and fundamentals remains a key consideration.
• Track companies supporting the build out of AI data centers by reviewing hand picked 55 AI infrastructure stocks that could benefit from rising demand for compute capacity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.